<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03030066</url>
  </required_header>
  <id_info>
    <org_study_id>DS1001-A-J101</org_study_id>
    <nct_id>NCT03030066</nct_id>
  </id_info>
  <brief_title>Study of DS-1001b in Patients With Gene IDH1-Mutated Gliomas</brief_title>
  <official_title>A Phase 1 Study of DS-1001b in Patients With IDH1 Mutated Gliomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Daiichi Sankyo, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics
      (PD) and anti-tumor activity of DS-1001b in patients with gliomas that harbor IDH1-R132
      mutations.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 19, 2017</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants with dose limiting toxicities</measure>
    <time_frame>21 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants experiencing an adverse event (AE)</measure>
    <time_frame>up to 36 months</time_frame>
    <description>AEs temporally associated with DS-1001b treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration curve (AUC) for DS-1001b</measure>
    <time_frame>up to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax) for DS-1001b</measure>
    <time_frame>up to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum plasma concentration (Tmax) for DS-1001b</measure>
    <time_frame>up to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in 2-hydroxyglutarate (2-HG) concentration in patient specimens after treatment with DS-1001b</measure>
    <time_frame>Baseline, up to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response to DS-1001b based on Response Assessment in Neuro-Oncology Criteria (RANO)</measure>
    <time_frame>up to 36 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Glioma</condition>
  <arm_group>
    <arm_group_label>Experimental Drug DS-1001b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DS-1001b</intervention_name>
    <description>Generic not assigned</description>
    <arm_group_label>Experimental Drug DS-1001b</arm_group_label>
    <other_name>Investigational</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Has histologically confirmed glioma with an IDH1-R132 mutation

          2. Has disease that has recurred or progressed following standard treatment including
             radiotherapy

          3. Has measurable lesion(s) as per RANO criteria

          4. Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2

        Exclusion Criteria:

          1. Has significant symptoms of increased intracranial pressure

          2. Has another active neoplasm

          3. Has active infection requiring systemic treatment

          4. Has a history of severe cardiac disease

          5. Has had prior treatment with any inhibitor targeting mutant IDH1

          6. Has had investigational drug treatment within 4 weeks prior to the first dose of study
             treatment

          7. Is a pregnant or lactating female
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Leader</last_name>
    <role>Study Director</role>
    <affiliation>Daiichi Sankyo, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daiichi Sankyo Contact for Clinical Trial Information</last_name>
    <phone>+81-3-6225-1111(M-F 9-5 JST)</phone>
    <email>dsclinicaltrial@daiichisankyo.co.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Cancer Center Hospital</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 18, 2017</study_first_submitted>
  <study_first_submitted_qc>January 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2017</study_first_posted>
  <last_update_submitted>January 2, 2018</last_update_submitted>
  <last_update_submitted_qc>January 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DS-1001b</keyword>
  <keyword>IDH1 mutation</keyword>
  <keyword>Developmental Phase I</keyword>
  <keyword>Glioma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

